Evidence mapPaperPMID 41683451Full record

ReviewMolecules (Basel, Switzerland)2026

Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease.

Junshuai Wang, Yuancong Xu, Yishu Yang, Botao Zhang, Sixu Chen, Zhaoyang Li, Haojia Zhu, Huai Yang, Hongtao Wang, Yubai Zhou and 3 more

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junshuai WangCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Yuancong XuCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0000-0002-1671-6156
Yishu YangCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Botao ZhangCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Sixu ChenCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Zhaoyang LiCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Haojia ZhuCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Huai YangCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Hongtao WangRailway Food Safety Management Engineering Technology Research Center, Zhengzhou Railway Vocational & Technology College, Zhengzhou 451400, China.
Yubai ZhouCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0000-0003-1066-7071
Peng CaoCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0000-0002-4616-5914
Baiqiang ZhaiRailway Food Safety Management Engineering Technology Research Center, Zhengzhou Railway Vocational & Technology College, Zhengzhou 451400, China.
Yong GongBeijing Synchrotron Radiation Facility, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.ORCID 0000-0002-4294-964X

Funding

Henan Provincial International Science and Technology Cooperation Project 252102520079R&D Program of Beijing Municipal Education Commission KZ202210005001Science and technology project of Henan Province 242102311178
6 · The paper itself

Abstract

Papain-like protease (PLpro), a crucial functional domain of the SARS-CoV-2 non-structural protein 3 (nsp3), plays a dual role in both hydrolyzing viral polyprotein precursors and modulating host immune responses. These critical functions position PLpro as a key target in the ongoing development of antiviral therapies for SARS-CoV-2. This review analyzes more than 100 PLpro-ligand co-crystal structures and summarizes the major binding modes between these ligands and PLpro. Most of these ligands bind to sites analogous to those targeted by the classical non-covalent inhibitor GRL0617, primarily involving the P3 and P4 subsites and the BL2 loop. Based on these structural insights, optimized inhibitors have expanded targeting beyond the canonical binding site to auxiliary regions such as the BL2 groove and the Val70 site, and in some cases toward the catalytic Cys111 buried within a narrow pocket. Certain ligands identified through various screening approaches bind to non-canonical or allosteric regions, such as the S1 and S2 sites or the zinc-finger domain, engaging PLpro through distinct interaction modes and thereby offering additional opportunities for PLpro inhibitor design. The review also discusses potential strategies for future PLpro inhibitor development informed by recent structural advances. Taken together, these structural and functional insights support ongoing efforts in the structure-guided design and optimization of PLpro inhibitors.

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSARS-CoV-2Viral Nonstructural ProteinsBinding SitesCatalytic DomainCoronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentHumansLigandsModels, MolecularAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like ProteasesLigandspapain-like protease, SARS-CoV-2Protease InhibitorsViral Nonstructural Proteinscrystal structuredrug discoverypapain-like proteaseSARS-CoV-2

Identifiers

PMID41683451
PMCPMC12899064

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.